INTRODUCTION: Checkpoint inhibitors have improved outcomes in metastatic melanoma, with 4-year overall survival (OS) of 46% for anti-PD-1 alone or 53% in combination with anti-CTLA-4. However, the median progression free survival is 6.9 and 11.5 months, respectively. Many who progress have gone on to alternative treatments, including surgery, yet the outcome of patients selected for surgery after checkpoint blockade remains unclear. METHODS: Patients who were treated with checkpoint blockade from 2003 to 2017, followed by metastasectomy, were identified from a prospectively maintained institutional melanoma database. Response to immunotherapy was assessed at the time of surgery. Patients were categorized as having responding, isolated progressing, or multiple progressing lesions. RESULTS: Of the 237 total patients identified, 208 (88%) had stage IV disease, and 29 (12%) had unresectable stage III disease at the start of immunotherapy. Median OS following first resection was 21 months. Median follow-up among survivors was 23 months. Complete resection at the first operation (n = 87, 37%) was associated with improved survival compared with patients with incomplete resection (n = 150, 63%) [median OS not reached (NR) vs. 10.8 months, respectively; 95% CI: 7.3, 14.8; p < 0.0001]. Patients resected for an isolated progressing or responding tumor had a longer median survival compared with those with multiple progressing lesions (NR vs. 7.8 months, 95% CI: 6.2, 11.2; p < 0.0001). CONCLUSIONS: Patients selected for surgical resection following checkpoint blockade have a relatively favorable survival, especially if they had a response to immunotherapy and undergo complete resection of isolated progressing or responding disease.
INTRODUCTION: Checkpoint inhibitors have improved outcomes in metastatic melanoma, with 4-year overall survival (OS) of 46% for anti-PD-1 alone or 53% in combination with anti-CTLA-4. However, the median progression free survival is 6.9 and 11.5 months, respectively. Many who progress have gone on to alternative treatments, including surgery, yet the outcome of patients selected for surgery after checkpoint blockade remains unclear. METHODS:Patients who were treated with checkpoint blockade from 2003 to 2017, followed by metastasectomy, were identified from a prospectively maintained institutional melanoma database. Response to immunotherapy was assessed at the time of surgery. Patients were categorized as having responding, isolated progressing, or multiple progressing lesions. RESULTS: Of the 237 total patients identified, 208 (88%) had stage IV disease, and 29 (12%) had unresectable stage III disease at the start of immunotherapy. Median OS following first resection was 21 months. Median follow-up among survivors was 23 months. Complete resection at the first operation (n = 87, 37%) was associated with improved survival compared with patients with incomplete resection (n = 150, 63%) [median OS not reached (NR) vs. 10.8 months, respectively; 95% CI: 7.3, 14.8; p < 0.0001]. Patients resected for an isolated progressing or responding tumor had a longer median survival compared with those with multiple progressing lesions (NR vs. 7.8 months, 95% CI: 6.2, 11.2; p < 0.0001). CONCLUSIONS:Patients selected for surgical resection following checkpoint blockade have a relatively favorable survival, especially if they had a response to immunotherapy and undergo complete resection of isolated progressing or responding disease.
Authors: Rebecca P Petersen; Steven I Hanish; John C Haney; Charles C Miller; William R Burfeind; Douglas S Tyler; Hilliard F Seigler; Walter Wolfe; Thomas A D'Amico; David H Harpole Journal: J Thorac Cardiovasc Surg Date: 2007-01 Impact factor: 5.209
Authors: T F Wood; L A DiFronzo; D M Rose; P I Haigh; S L Stern; L Wanek; R Essner; D L Morton Journal: Ann Surg Oncol Date: 2001-09 Impact factor: 5.344
Authors: Jeffrey A Sosman; James Moon; Ralph J Tuthill; James A Warneke; John T Vetto; Bruce G Redman; P Y Liu; Joseph M Unger; Lawrence E Flaherty; Vernon K Sondak Journal: Cancer Date: 2011-03-31 Impact factor: 6.860
Authors: Elizabeth A Mittendorf; Sherry J Lim; Chris W Schacherer; Anthony Lucci; Janice N Cormier; Paul F Mansfield; Jeffrey E Gershenwald; Merrick I Ross; Jeffrey E Lee Journal: Am J Surg Date: 2008-03 Impact factor: 2.565
Authors: F J Collinson; T K Lam; W M J Bruijn; J H W de Wilt; M Lamont; J F Thompson; R F Kefford Journal: Ann Surg Oncol Date: 2008-04-01 Impact factor: 5.344
Authors: Heather B Neuman; Ami Patel; Christine Hanlon; Jedd D Wolchok; Alan N Houghton; Daniel G Coit Journal: Ann Surg Oncol Date: 2007-08-07 Impact factor: 5.344
Authors: Ashley C Mays; Bharat Yarlagadda; Virginie Achim; Ryan Jackson; Patrik Pipkorn; Andrew T Huang; Karthik Rajasekaran; Shaum Sridharan; Andrew J Rosko; Ryan K Orosco; Andrew M Coughlin; Mark K Wax; Yelizaveta Shnayder; William C Spanos; Donald Gregory Farwell; Lee S McDaniel; Matthew M Hanasono Journal: Head Neck Date: 2021-01-08 Impact factor: 3.147
Authors: Mohammed Safi; Mahmoud Al-Azab; Chenxing Jin; Dario Trapani; Salem Baldi; Salah Adlat; Aman Wang; Bashir Ahmad; Hamza Al-Madani; Xiu Shan; Jiwei Liu Journal: Front Immunol Date: 2021-11-16 Impact factor: 7.561
Authors: Stephanie A Blankenstein; Maureen J B Aarts; Franchette W P J van den Berkmortel; Marye J Boers-Sonderen; Alfons J M van den Eertwegh; Margreet G Franken; Jan Willem B de Groot; John B A G Haanen; Geke A P Hospers; Ellen Kapiteijn; Djura Piersma; Rozemarijn S van Rijn; Karijn P M Suijkerbuijk; Albert J Ten Tije; Astrid A M van der Veldt; Gerard Vreugdenhil; Michel W J M Wouters; Alexander C J van Akkooi Journal: Cancers (Basel) Date: 2020-05-07 Impact factor: 6.639